Home /Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer

Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer

Submitted by dcc on Mon, 02/14/2022 - 15:00
TitleEfficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer
Publication TypeJournal Article
Year of Publication2021
AuthorsFalandry, C, Rousseau, F, Mouret-Reynier, M-A, Tinquaut, F, Lorusso, D, Herrstedt, J, Savoye, A-M, Stefani, L, Bourbouloux, E, Sverdlin, R, D’Hondt, V, Lortholary, A, Brachet, P-E, Zannetti, A, Malaurie, E, Venat-Bouvet, L, Trédan, O, Mourey, L, Pujade-Lauraine, E, Freyer, G
Corporate AuthorsGroupe d’Investigateurs Nationaux pour l’Étude des Cancers de l’Ovaire et du sein (GINECO)
JournalJAMA Oncology
Volume7
Issue6
Pagination853
Date PublishedJan-06-2021
ISSN2374-2437
URLhttps://jamanetwork.com/journals/jamaoncology/fullarticle/2778657https://jamanetwork.com/journals/jamaoncology/articlepdf/2778657/jamaoncology_falandry_2021_oi_210008_1623352005.99937.pdf
DOI10.1001/jamaoncol.2021.0696
Short TitleJAMA Oncol